Bright Pharma Engineering Limted Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 17 Year, 2 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 11.68 Cr
as on 16-11-2024
- Revenue -47.51%
(FY 2023)
- Profit -87.61%
(FY 2023)
- Ebitda -77.32%
(FY 2023)
- Net Worth 2.78%
(FY 2023)
- Total Assets 17.26%
(FY 2023)
About Bright Pharma Engineering Limted
The Company is engaged in the Machinery And Equipment Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹11.68 Cr.
Vijay Panchal, Dilip Panchal, Chimanlal Panchal, and One other member serve as directors at the Company.
- CIN/LLPIN
U33100MH2008PTC177333
- Company No.
177333
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Jan 2008
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Bright Pharma Engineering Limted?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vijay Panchal  | Director | 04-Jan-2008 | Current |
| Dilip Panchal | Director | 04-Jan-2008 | Current |
| Chimanlal Panchal | Director | 04-Jan-2008 | Current |
| Smita Panchal | Director | 04-Jan-2008 | Current |
Financial Performance of Bright Pharma Engineering Limted.
Bright Pharma Engineering Private Limted, for the financial year ended 2023, experienced significant reduction in revenue, with a 47.51% decrease. The company also saw a substantial fall in profitability, with a 87.61% decrease in profit. The company's net worth moved up by a moderate rise of 2.78%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bright Pharma Engineering Limted?
In 2022, Bright Pharma Engineering Limted had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 17 Nov 2022 | ₹2.51 M | Open |
Others Creation Date: 16 Oct 2019 | ₹11.42 Cr | Open |
How Many Employees Work at Bright Pharma Engineering Limted?
Unlock and access historical data on people associated with Bright Pharma Engineering Limted, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bright Pharma Engineering Limted, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bright Pharma Engineering Limted's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
